

## EDUCATION, SCIENCE AND TRAINING

### SENATE LEGISLATION COMMITTEE - QUESTIONS ON NOTICE 2005-2006 BUDGET ESTIMATES HEARING

**Outcome:** ANSTO

**Output Group:** ANSTO

#### **DEST Question No. E251\_06**

Senator Carr provided in writing.

#### **Question:**

Paragraph 1.54 of the Quarterly Report says about ARPANSA's review of ANSTO's compliance with the Organisational Special License conditions (Part 2.3 of the ANSTO Handbook):

*"With the exception of one condition, compliance with all license conditions was demonstrated... [A]n amendment to [was] made to the Radiopharmaceuticals Facility License to add another special license condition."*

Please provide details of the one exception to compliance with the License conditions?

#### **Answer:**

*Exception to compliance with license conditions*

ANSTO has provided the following response:

The "ANSTO Handbook" issued by the CEO of ARPANSA in December 2000 (which can be found at [www.arpansa.gov.au/pubs/ansto\\_hndbk.pdf](http://www.arpansa.gov.au/pubs/ansto_hndbk.pdf)) contained a large number of "Special Licence Conditions" applying to the organisation as a whole. The ARPANSA review of ANSTO's Organisational Special Licence Conditions referred to in the Quarterly Report found that all but one of those conditions had been fully complied with across the organisation. The outstanding condition, numbered 2.3.8, required ANSTO to conduct a Dose Constraint Review. At the time of the ARPANSA review referred to in the Quarterly Report, that had been done everywhere in the organisation except in the radiopharmaceuticals production area. ANSTO was consequently advised that condition 2.3.8, like all the other Special Licence Conditions, would be removed from the organisational conditions, and a similar condition added to the Radiopharmaceuticals Facility Licence. This added condition has since been met, and ANSTO understands that ARPANSA are intending to formally remove it from the Radiopharmaceuticals Facility Licence.